CHALLENGES AND RECENT DEVELOPMENTS ASSOCIATED WITH VACCINE ANTIGENS PRODUCTION AGAINST HELICOBACTER PYLORI

  • RAMBOD BARZIGAR JSS Research Foundation, SJCE Technical Campus, Mysore 570006
  • NANJUNDAPPA HARAPRASAD 2 JSS Science and Technology University,SJCE,Technical Campus,Mysore-570006
  • BASARALU YADURAPPA SATHISH KUMAR JSS Research Foundation, SJCE Technical Campus, Mysore 570006, Postgraduate Department of Biotechnology, JSS College, Ooty Road, Mysore 570025
  • MOHAMMAD JAVAD MEHRAN JSS Research Foundation, SJCE Technical Campus, Mysore 570006

Abstract

Around half of the world’s population faces Helicobactor pylori (H. pylori) infection. Enormous progress has been made to understand the bacterial pathogenesis process and pathogen interaction with eukaryotic cells but infectious diseases are still the cause of premature death of humans around the world. H. pylori is categorized under class I carcinogen by the WHO based on clinical study results. This review paper discusses various attempts made to establish an efficient vaccine to manage H. pylori infection. Some of the problems in developing an efficient vaccine against H. pylori are recurrent or persistent infection, insufficient knowledge about the action specifically in case of probiotics, development of antibiotic resistance, and cost of therapy are noted. This research may come up with transient Nicotiana benthamiana with suitable H. pylori genes expressed as antigenic proteins, which can be used for further studies to develop a vaccine for gastric ulcer/cancer and generate good scientific data that can be helpful for scientists and researchers in this field.


This review article for monitors’ current approaches monitoring H. pylori infection since 1998 to 2019 using world-wide recognized journals and books, questioning its efficacies and whether these strategies help eradicate or there is a need to focus on several diversions. We provide scientific recommendations in eliminating H. pylori through vaccination along with addressing the preventive vaccine for this pathogen rather than using defeated treatments with plant-based nil side effects solution. The information relies on the available content in Google Scholar and PubMed using the keywords listed below.

Keywords: Helicobacter pylori, Helicobacter pylori neutrophil-activating protein (HP-NAP), Cytotoxin-associated genes pathogenicity island (cagPAI), VacA, UreB, Tumoural necrosis factor-alpha (TNF-α)

References

1. Shaymaa Hasan Abbas, Manal Khalid Abdul Ridha, Akram Ajeel Najeb. Potential benefits of curcumin adjuvant therapy to the standard Helicobacter pylori eradication therapy in patients with peptic ulcer disease. Asian J Pharm Clin Res 2017;10:313-7.
2. Bianca Bauer, Thomas F Meyer. The human gastric pathogen Helicobacter pylori and its association with gastric cancer and ulcer disease. Hindawi; 2011.
3. Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000;191:1467–76.
4. Polenghi A, Bossi F, Fischetti F, Durigutto P, Cabrelle A, Tamassia N, et al. The neutrophil-activating protein of Helicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo. J Immunol 2007;178:1312–20.
5. Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A, Benagiano M, et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006;116:1092–101.
6. Sanguk Kim, Aaron K Chamberlain, James U Bowie. Membrane channel structure of Helicobacter pylori vacuolating toxin: role of multiple GXXXG motifs in cylindrical channels. Proc Natl Acad Sci USA 2004;101:5988-91.
7. Molinari M, Salio M, Galli C, Norais N, Rappuoli R, Lanzavecchia A, et al. Selective inhibition of Ii-dependent antigen presentation by Helicobacter pylori toxin VacA. J Exp Med 1998;187:135–40.
8. Yamasaki E, Wada A, Kumatori A, Nakagawa I, Funao J, Nakayama M, et al. Helicobacter pylori vacuolating cytotoxin induces activation of the pro-apoptotic proteins Bax and Bak, leading to cytochrome c release and cell death, independent of vacuolation. J Biol Chem 2006;281:11250–9.
9. Ummay Mahfuza Shapla, Jinat Raihan, Asiful Islam, Fahmida Alam, Solayman, Siew Hua Gan, et al. Propalis: the future therapy against Helicobactor pylori-mediated gastrointestinal diseases. J Appl Biomed 2018;16:81-91.
10. Amin Talebi Bezmin Abadi. Vaccine against Helicobacter pylori: Inevitable approach. World J Gastroenterol 2016;22:3150–7.
11. Philip Sutton, Joanne M Boag. Status of vaccine research and development for Helicobacter pylori. Vaccine 2019;37:7295–9.
12. Steven F Moss, Leonard Moise, Dong-Soo Lee, Woojin Kim. HelicoVax: Epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 2011;29:2085-91.
13. Xinyang Li, Yingying Xing, Le Guo, XiaoboLv, Hui Song, Tao Xi. Oral immunization with recombinant Lactococcus lactis delivering a multi-epitope antigen CTB-UE attenuates Helicobacter pylori infection in mice. Pathogens Disease 2014;72:78–86.
14. Florian Ander, Markus Gerhard. Helicobacter pylori vaccination: is there a path to protection? World J Gastroenterol 2014;20:11939-49.
15. Prinz CM Schoniger, Rad R, Becker I, Keiditsch E, Wagenpfeil S, Classen M, et al. Key importance of the Helicobacter pylori adherence factor blood group antigen-binding adhesin during chronic gastric inflammation. Cancer Res 2001;61:1903-9.
16. Yamaoka Y, Kita M, Kodama T, Imamura S, Ohno T, Sawai N, et al. Helicobacter pylori infection in mice: role of outer membrane proteins in colonization and inflammation. Gastroenterology 2002;123:1992-2004.
17. Mahdavi J, Sondén B, Hurtig M, Olfat FO, Forsberg L, Roche N, et al. Helicobacter pylori Sab Aadhesin in persistent infection and chronic inflammation. Science 2002;297:573-8.
18. de Jonge R, Pot RG, Loffeld RJ, van Vliet AH, Kuipers EJ, Kusters JG. The functional status of the Helicobacter pylori sabB adhesin gene as a putative marker for disease outcome. Helicobacter 2004;9:158-64.
19. Kudo T, Nurgalieva ZZ, Conner ME, Crawford S, Odenbreit S, Haas R, et al. Correlation between Helicobacter pylori OipA protein expression and oipA gene switch status. J Clin Microbiol 2004;42:2279-81.
20. de Jonge R, Durrani Z, Rijpkema SG, Kuipers EJ, van Vliet AHM, Kusters JG. Role of the Helicobacter pylori outer membrane proteins AlpA and AlpB in the colonization of the guinea pig stomach. J Med Microbiol 2004;53:375-9.
21. Montemurro PH, Nishioka WG, Dundon M, de Bernard G, Del Giudice, Rappuoli R, et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a potent stimulant of mast cells. Eur J Immunol 2002;32:671-6.
22. Occhialini A, Marais A, Alm R, Garcia F, Sierra R, Megraud F. Distribution of open reading frames of plasticity region of strain J99 in Helicobacter pylori strains isolated from gastric carcinoma and gastritis patients in Costa Rica. Infect Immun 2000;68:6240-9.
23. Donahue JP, Peek RM, Van Doorn LJ, Thompson SA, Xu Q, Blaser MJ, et al. Analysis of iceA1 transcription in Helicobacter pylori. Helicobacter 2000;5:1-12.
24. Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 2005;128:833-48.
25. John D Clements, Elizabeth B Norton. The mucosal vaccine adjuvant LT (R192G/l211A) or dm LT. mSphere 2018;3:215-8.
26. Tiruvayipati Suma Avasthi, Singamaneni Haritha Devi, Todd D Taylor, Narender Kumar, Ramani Baddam, Shinji Kondo, et al. Genomes of two chronological isolates (Helicobacter pylori 2017 and 2018) of the West African Helicobacter pylori strain 908 obtained from a single patient. J Bacteriol 2011;193:3385-6.
27. Amjad Ali, Anam Naz, Siomar C Soares, Marriam Bakhtiar, Sandeep Tiwari, Syed S Hassan, et al. Pan-genome analysis of human gastric pathogen H. pylori: comparative genomics and pathogenomics approaches to identify regions associated with pathogenicity and prediction of potential core therapeutic targets. Biomed Res Int 2015. DOI:10.1155/2015/139580
28. Peter R Jungblut, Michael Hecker. Proteomics of microbial pathogens. Wiley Publications; 2002.
29. Le Guo, Kunmei Liu, Guangxian Xu, Xiaokang Li. Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a BALB/c mice model. Appl Microbiol Biotechnol 2012;95:1437-44.
30. Kondethimmanahalli Chandramouli, Pei-Yuan Qian. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics 2009. DOI:10.4061/2009/239204
31. Timothy W Hand. The role of the microbiota in shaping infectious immunity. Trends Immunol 2016;37:647-58.
32. Jacques Pappo, Steven Czinn, John Nedrud. Helicobacter pylori: physiology and Genetics. Chapter 37 Vaccines; 2001.
33. Ivan YC Lin, Thi Thu Hao Van, Peter M Smooker. Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery. Vaccines (Basel) 2015;3:940-72.
34. Elzbieta K, Jagusztyn Krynicka, Renata Godlewska. New approaches for helicobactor vaccine development–difficulties and progress. Polish J Microbiol 2008;57:3-9.
35. Partha Krishnamurthy, Mary Parlow, Jason B Zitzer, Nimish B Vakil, Harry LT Mobley, Marilyn Levy. Helicobacter pylori containing only cytoplasmic urease is susceptible to acid. Infect Immun 1998;66:5060-6.
36. Smythies LE, Novak MJ, Waites KB, Lindsey JR, Morrow CD, Smith PD. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 2005;23:901-9.
37. Agnieszka Wyszy?ska, Patrycja Kobierecka, Jacek Bardowski, El?bieta Katarzyna Jagusztyn Krynicka. Lactic acid bacteria-20 y exploring their potential as live vectors for mucosal vaccination. Appl Microbiol Biotechnol 2015;99:2967-77.
38. Johannes G Kusters, Arnoud HM van Vliet, Ernst J Kuipers. Pathogenesis of Helicobacter pylori Infection. Clin Microbiol Rev 2006;19:449-90.
39. David N Baldwin, Benjamin Shepherd, Petra Kraemer, Michael K Hall, Laura K Sycuro, Delia M Pinto-Santini. Identification of Helicobacter pylori genes that contribute to stomach colonization. Infect Immun 2007;75:1005-16.
40. Hatzifoti C, Roussel Y, Harris AG, Wren BW, Morrow JW, Bajaj Elliott M. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. Helicobacter 2006;11:113-22.
41. Moll H. Antigen delivery by dendritic cells. Int J Med Microbiol 2004;294:337-44.
42. Garmony HS, Brown KA, Titball RW. Salmonella vaccines for use in human: present and future perspectives. FEMS Microbiol Rev 2002;26:339-53.
43. Papastergiou V, Georgopoulos S, Karatapanis S. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014;20:9898-911.
44. Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: past, present and future. World J Gastrointest Pathophysiol 2014;5:392-9.
45. Wang F, Feng J, Chen P, Liu X, Ma M, Zhou R, et al. Probiotics in Helicobacter pylori eradication therapy: systematic review and network meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:466-75.
46. Kamila Goderska, Sonia Agudo Pena, Teresa Alarcon. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol 2018;102:1-7.
47. Anne Zemella, Lena Thoring, Christian Hoffmeister, Stefan Kubick. Cell-free protein synthesis: pros and cons of prokaryotic and eukaryotic systems. Chembiochem 2015;16:2420-31.
48. Takaiwa F. Transgenic rice seed as a nutriceutical delivery system. CAB Rev 2007;2:4.
49. Gu Q, Han N, Liu J, Zhu M. Expression of Helicobacter pylori urease subunit B gene in transgenic rice. Biotechnol Lett 2006;28:1661-6.
50. Zhang H, Liu M, Li Y, Zhao Y, He H, Yang G, et al. Oral immunogenicity and protective efficacy in mice of a carrot-derived vaccine candidate expressing UreB subunit against Helicobacter pylori. Protein Expr Purif 2010;69:127-31.
51. Ganapathi Narasimhulu, Jamaludin Mohamed. Medicinal phytochemical and pharmacological properties of kesum (Polygonum minus linn.): a mini review. Int J Pharm Pharm Sci 2014;6:682-8.
52. Brodzik R, Gaganidze D, Hennig J, Muszy?ska G, Koprowski H, Sirko A. Transgenic plants as a potential source of an oral vaccine against Helicobacter pylori. Progress Biotechnol 2000;17:35-42.
53. Zhang H, Zhang X, Liu M, Zhang J, Li Y, Zheng CC. Expression and characterization of Helicobacter pylori heat-shock protein a (HspA) protein in transgenic tobacco (Nicotianatabacum) plants. Biotechnol Appl Biochem 2006;43:33-8.
54. Yang CY, Chen SY, Duan GC. Transgenic peanut (Arachishypogaea L.) expressing the urease subunit B gene of Helicobacter pylori. Curr Microbiol 2011;63:387-91.
55. Irina Kalbina, Lars Engstrand, So ren Andersson, A ke Strid. Expression of Helicobacter pylori TonB protein in transgenic Arabidopsis Thaliana: toward production of vaccine antigens in plants. Helicobacter. Blackwell Publishing Ltd; 2010.
56. Ngan LT, Moon JK, Shibamoto T, Ahn YJ. Growth-inhibiting, bactericidal, and urease inhibitory effects of paeonialactiflora root constituents and related compounds on antibiotic-susceptible and-resistant strains of Helicobacter pylori. J Agric Food Chem 2012;60:9062-73.
57. Paulo L, Oleastro M, Gallardo E, Queiroz JA, Domingues F. Anti-Helicobacter pylori and urease inhibitory activities of resveratrol and red wine. Food Res Int 2011;44:964-9.
58. Amin M, Anwar F, Naz F, Mehmood T, Saari N. Anti-Helicobacter pylori and urease inhibition activities of some traditional medicinal plants. Molecules 2013;18:2135-49.
59. Julia Bally, Hyungtaek Jung, Cara Mortimer, Fatima Naim, Joshua G Philips, Roger Hellens. The rise and rise of Nicotiana benthamiana: a plant for all reasons. Annual Review of Phytopathology 2018;56:405-26.
60. Akhtar S, Briddon RW, Mansoor S. Reactions of Nicotiana species to inoculation with monopartite and bipartite begomo viruses. Virol J 2011;8:475.
61. Dhary Alewy Almashhadany. Application of stool antigen test for monitoring Helicobacter pylori among human in Erbil governorate, Kurdistan region/Iraq. Int J Pharm Pharm Sci 2018;10:49-53.
Statistics
57 Views | 97 Downloads
Citatons
How to Cite
BARZIGAR, R., HARAPRASAD, N., KUMAR, B. Y. S., & MEHRAN, M. J. (2020). CHALLENGES AND RECENT DEVELOPMENTS ASSOCIATED WITH VACCINE ANTIGENS PRODUCTION AGAINST HELICOBACTER PYLORI. International Journal of Applied Pharmaceutics, 12(4), 45-50. https://doi.org/10.22159/ijap.2020v12i4.37722
Section
Review Article(s)